8-K: LENZ Therapeutics Reports Q3 2025 Results, VIZZ Launch Success

LENZ Therapeutics announced its third quarter 2025 financial results, highlighting the successful commercial launch of VIZZ for presbyopia and a strong cash position.

Summary

• FDA approval of VIZZ (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia was announced on July 31, 2025, ahead of its August 8, 2025 PDUFA date.
• Commercial launch of VIZZ initiated in October 2025, with broad product availability anticipated in mid-Q4 2025.
• Over 2,500 Eye Care Professionals (ECPs) prescribed VIZZ, with 40% prescribing multiple times, resulting in over 5,000 prescriptions filled through October 2025.
• Pro forma cash, cash equivalents, and marketable securities were approximately $324.0 million as of September 30, 2025.
• Net loss for the three months ended September 30, 2025, was $16.7 million, or $0.59 per share, compared to a net loss of $10.2 million, or $0.38 per share, for the same period in 2024.
• Selling, General and Administrative (SG&A) expenses increased to $27.6 million in Q3 2025 from $6.5 million in Q3 2024, primarily due to personnel growth and pre-commercial marketing for the VIZZ launch.
• Research and Development (R&D) expenses decreased to $3.8 million in Q3 2025 from $6.5 million in Q3 2024, driven by the substantial completion of the Phase 3 CLARITY study.
• A partnership with Sarah Jessica Parker as direct-to-consumer (DTC) campaign spokesperson was announced, with the campaign anticipated to launch in Q1 2026.
• Received $10 million in milestone payments from CORXEL Pharmaceuticals in China for NDA submission and US VIZZ approval.
• An exclusive license and commercialization agreement was signed with Laboratoires Tha for VIZZ in Canada, potentially yielding over $70 million in upfront, regulatory, and commercial milestone payments, plus tiered, double-digit royalties on net sales.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the successful FDA approval and initial commercial launch of VIZZ, strong ECP adoption, significant international licensing deals, and a robust pro forma cash position. The increased net loss is primarily attributable to strategic investments in the commercial launch, which is a necessary and expected expenditure for a new product introduction.

Positives

• FDA approval of VIZZ for presbyopia was received on July 31, 2025, ahead of its PDUFA date.
• Successful initial commercial launch of VIZZ in October 2025, demonstrating strong ECP engagement with over 2,500 unique prescribers and over 5,000 prescriptions filled through October.
• High ECP awareness (90%) and confidence in VIZZ, supported by extensive sales calls and product samples.
• Partnership with Sarah Jessica Parker announced for a direct-to-consumer campaign launching in Q1 2026.
• Received $10 million in milestone payments from CORXEL Pharmaceuticals for international development and US approval.
• Secured a licensing agreement with Laboratoires Tha for Canada, with potential payments exceeding $70 million plus royalties.
• Strong pro forma cash, cash equivalents, and marketable securities of approximately $324.0 million as of September 30, 2025, anticipated to fund operations to post-launch positive cash flow.
• Decrease in R&D expenses due to the substantial completion of the Phase 3 CLARITY study.

Negatives

• Net loss increased to $16.7 million in Q3 2025 from $10.2 million in Q3 2024.
• Selling, General and Administrative (SG&A) expenses significantly increased to $27.6 million in Q3 2025 from $6.5 million in Q3 2024, primarily due to commercial launch activities and increased headcount.

Future Outlook

The company anticipates broad commercial product availability for VIZZ in mid-Q4 2025. A direct-to-consumer campaign featuring Sarah Jessica Parker is slated for launch in Q1 2026. The pro forma cash position is expected to fund operations to post-launch positive cash flow. LENZ also plans to continue establishing international licensing partnerships for VIZZ.

Management Comments

• "We are very pleased with the first weeks of the VIZZ launch as we introduce our exciting new solution for the treatment of presbyopia into the marketplace and have been highly encouraged by the enthusiasm from the ECP community, as evidenced by the over 2,500 unique prescribers and impressively over 5,000 prescriptions filled through October." Eef Schimmelpennink, President and Chief Executive Officer.
• "Early patient feedback has been very positive, and it is undisputed that VIZZ is highly effective at restoring near vision with rapid onset and long duration." Eef Schimmelpennink, President and Chief Executive Officer.
• "The months ahead promise to continue to be very exciting, and we are proud to announce today our partnership with Sarah Jessica Parker as campaign spokesperson to lead the VIZZ DTC campaign which we intend to launch in Q1 2026." Eef Schimmelpennink, President and Chief Executive Officer.

Industry Context

Presbyopia, affecting approximately 128 million adults in the U.S. and 1.8 billion globally, is a significant and growing market. VIZZ, as the first and only FDA-approved aceclidine-based eye drop, offers a novel, non-surgical solution for near vision restoration, potentially disrupting the market dominated by reading glasses, bifocals, or multifocal contact lenses. The company's focus on ECP engagement and a high-profile DTC campaign aims to capture a substantial share of this large patient population.

Stakeholder Impact

• Shareholders: Positive impact from successful product launch, potential revenue growth, and strong cash position. Increased net loss is a short-term investment for future growth.
• Patients: VIZZ offers a new, effective treatment option for presbyopia, improving near vision.
• Eye Care Professionals (ECPs): Provided with a new prescription option for presbyopia, supported by samples and marketing.
• Employees: Growth in headcount, including an 88-territory sales force, indicates job creation and expansion.

Next Steps

• Achieve broad commercial product availability for VIZZ in mid-Q4 2025.
• Launch the direct-to-consumer campaign with Sarah Jessica Parker in Q1 2026.
• Continue establishing international licensing partnerships for VIZZ.
• Management to host a conference call on November 5, 2025, at 8:30 am EST.

Key Dates

Recommendation

The company has achieved a critical milestone with the FDA approval and successful initial commercial launch of VIZZ, addressing a large unmet medical need. Early adoption by ECPs and prescription numbers are highly encouraging. Strategic partnerships and a robust cash position provide a strong foundation for future growth and market penetration. While the net loss increased, it is a direct result of necessary investments in commercialization, which are expected to yield significant returns. The outlook for VIZZ and the company's financial stability warrant a strong buy recommendation.

Keywords

LENZ Therapeutics, VIZZ, aceclidine, presbyopia, eye drops, ophthalmic solution, FDA approval, commercial launch, pharmaceuticals, Q3 2025 earnings, financial results, biotechnology, near vision, Sarah Jessica Parker